NOV 17, 202664 MINS READ
Croscarmellose sodium is synthesized through internal cross-linking of sodium carboxymethylcellulose achieved by lowering pH during manufacture and applying controlled heating 1. This cross-linking process creates a three-dimensional fibrous network wherein carboxymethyl substituents (-CH₂COONa) are distributed along cellulose backbone chains and covalently bridged at intervals. The resulting polymer exhibits a particle size distribution typically characterized by 90% of particles ≤44.5 μm in standard grades 1, though fine particle variants with median particle size (D50) of 5–36 μm and volume mean diameter (D[4,3]) ≤40 μm have been developed to enhance specific surface area (≥0.3 m²/g) and disintegration efficiency 6,7,9.
The hygroscopic nature of croscarmellose sodium arises from multiple molecular features:
Importantly, moisture content in croscarmellose sodium is not merely residual water from manufacturing; it represents an equilibrium state governed by ambient relative humidity (RH) and temperature. Typical commercial grades equilibrate to approximately 5–7% moisture content at 25°C/60% RH, with higher RH environments (e.g., 75% RH) driving moisture levels toward 8–10% 1,6. This dynamic equilibrium necessitates rigorous control during storage, handling, and formulation to prevent variability in functional performance.
Accurate quantification of moisture content is essential for quality control, regulatory compliance, and formulation optimization. Several analytical methods are employed, each with distinct principles, advantages, and limitations:
Karl Fischer (KF) titration remains the gold standard for moisture determination in pharmaceutical excipients due to its high specificity for water. The method relies on the stoichiometric reaction between iodine, sulfur dioxide, and water in the presence of a base (typically imidazole) and methanol. For croscarmellose sodium, coulometric KF titration is preferred when moisture content is below 1%, while volumetric KF is suitable for higher levels (1–10%) 1,6. Sample preparation involves dispersing 0.5–1.0 g of croscarmellose sodium in anhydrous methanol with vigorous stirring to ensure complete water extraction from the fibrous matrix. Typical precision (relative standard deviation) is <2%, and results are reported as % w/w moisture.
TGA measures mass loss as a function of temperature under controlled atmosphere (nitrogen or air). For croscarmellose sodium, a heating ramp of 10°C/min from ambient to 150°C is commonly applied, with moisture loss typically complete by 120°C 1,6. The method is rapid (15–20 minutes per sample) and requires minimal sample preparation (5–10 mg). However, TGA may overestimate moisture if volatile organic impurities or residual solvents are present. Derivative thermogravimetry (DTG) can help distinguish moisture loss (sharp peak at 80–100°C) from thermal decomposition events (onset >200°C).
LOD is a pharmacopeial method (USP <731>, Ph.Eur. 2.2.32) involving drying a known mass of croscarmellose sodium (typically 1–2 g) in a convection oven at 105°C for 2–4 hours until constant weight is achieved 1,4. The method is simple and widely accessible but less specific than KF titration, as it measures total volatile content rather than water alone. For croscarmellose sodium, LOD values typically range from 5% to 10% depending on initial equilibration conditions and particle size 1,6,10.
NIR spectroscopy offers non-destructive, real-time moisture monitoring by measuring water-associated absorption bands (primarily the O-H stretch overtone at ~1940 nm). Calibration models are developed using partial least squares (PLS) regression against reference KF or LOD data. Once validated, NIR enables rapid (<1 minute) moisture determination directly in bulk powder or through transparent packaging. This technique is increasingly adopted for in-process control during granulation and blending operations 6,7.
Moisture content profoundly affects the functional performance of croscarmellose sodium as a super-disintegrant. The relationship is non-linear and depends on formulation composition, compaction force, and tablet hardness.
Experimental data from model tablet formulations containing croscarmellose sodium at 0.5–80% w/w in mannitol matrix reveal that disintegration time is minimized when croscarmellose sodium moisture content is maintained between 5% and 8% 10,15,16. At moisture levels below 5%, the material exhibits reduced swelling capacity due to insufficient hydration of carboxylate groups, resulting in slower water uptake and prolonged disintegration (e.g., 180–240 seconds at 10 kN compaction force for tablets with 2% croscarmellose sodium at 3% moisture vs. 60–90 seconds at 6% moisture) 10,15.
Conversely, moisture content exceeding 10% can lead to premature swelling during tablet compression, causing:
Fine particle croscarmellose sodium (D50 = 5–25 μm) exhibits higher specific surface area (0.3–0.5 m²/g) compared to standard grades (D50 = 34 μm, specific surface area ~0.2 m²/g), resulting in faster moisture sorption kinetics and greater equilibrium moisture content at equivalent RH 6,7,9. For instance, fine particle croscarmellose sodium equilibrated at 60% RH typically contains 7–9% moisture, whereas standard grades contain 5–7% under identical conditions 6,9. This difference translates to enhanced disintegration efficiency: tablets containing 10% fine particle croscarmellose sodium (D50 = 20 μm) disintegrate in 30–45 seconds at 8 kN compaction force, compared to 60–75 seconds for standard grade at equivalent moisture content 6,7,9.
However, the higher moisture affinity of fine particle grades necessitates stringent humidity control during storage and processing. Exposure to >75% RH for extended periods (>24 hours) can elevate moisture content to 12–15%, compromising flowability (Carr index increases from 18–22% to 28–35%) and causing agglomeration 6,9.
Effective moisture management requires integration of material selection, process design, and packaging strategies tailored to the specific formulation and target storage conditions.
Formulators should specify croscarmellose sodium grades with defined moisture content ranges (e.g., 5.0–7.0% by KF titration) in raw material specifications. Upon receipt, excipient lots should be equilibrated in a controlled environment (e.g., 25°C/50% RH for 48 hours) prior to use to ensure batch-to-batch consistency 1,6,10. For moisture-sensitive APIs, low-moisture croscarmellose sodium variants (3–5% moisture) can be prepared by drying at 80°C under vacuum for 4–6 hours, though this may reduce disintegration efficiency by 10–15% and require compensatory increases in disintegrant concentration (e.g., from 4% to 5–6% w/w) 4,10.
In wet granulation formulations, the hygroscopic nature of croscarmellose sodium must be balanced against the need for adequate moisture during granule formation. A two-stage disintegrant addition strategy is commonly employed:
Granulation endpoint is typically defined by achieving 2–4% total formulation moisture (by LOD), with subsequent drying at 50–60°C in a fluid bed dryer until moisture content is reduced to 1.5–2.5% 2,5. Over-drying (<1% moisture) can impair croscarmellose sodium functionality, necessitating re-equilibration prior to compression.
Tablet hardness and compaction force significantly modulate the impact of croscarmellose sodium moisture content on disintegration. At low compaction forces (4–6 kN), tablets containing croscarmellose sodium with 5–8% moisture exhibit disintegration times of 30–60 seconds regardless of particle size, as the porous tablet structure facilitates rapid water penetration 10,15,16. However, at high compaction forces (10–12 kN), tablets become denser (porosity decreases from 20–25% to 10–15%), and disintegration time increases to 90–150 seconds for standard croscarmellose sodium (D50 = 34 μm) but only 45–75 seconds for fine particle grades (D50 = 20 μm) at equivalent moisture content 10,15,16.
To mitigate the adverse effects of high compaction force, formulators can:
Croscarmellose sodium should be stored in moisture-barrier packaging (e.g., polyethylene-lined fiber drums or multi-wall paper bags with inner polyethylene liner) to prevent moisture uptake during storage. Recommended storage conditions are 15–25°C and ≤60% RH 1,6. For long-term stability (>12 months), desiccant sachets (silica gel or molecular sieves) should be included in packaging to maintain RH below 50%. Tablets containing croscarmellose sodium should be packaged in blister packs (PVC/PVDC or Alu/Alu) or HDPE bottles with induction-sealed foil liners and desiccant canisters to prevent moisture ingress and maintain disintegration performance throughout the product shelf life (typically 24–36 months) 2,4,5.
Croscarmellose sodium is widely utilized across diverse therapeutic categories, with moisture content optimization being particularly critical in formulations containing hygroscopic or moisture-labile APIs.
Entacapone and nitecapone, catechol-O-methyltransferase (COMT) inhibitors used in Parkinson's disease management, are formulated with croscarmellose sodium at 10–14% w/w to achieve rapid disintegration (<3 minutes) and dissolution (>80% in 30 minutes) 4. Moisture content of croscarmellose sodium in these formulations is maintained at 6–8% to balance disintegration efficiency with chemical stability, as entacapone undergoes hydrolytic degradation in the presence of excess moisture (degradation rate increases by 2–3 fold when formulation moisture exceeds 4%) 4. Tablets are packaged in Alu/Alu blisters with desiccant to ensure <2% formulation moisture throughout the 24-month shelf life 4.
Croscarmellose sodium is incorporated into extended-release matrices at 3–20% w/w in combination with alkali agents (sodium carbonate, potassium carbonate) and hydrophobic polymers (ethyl cellulose, hypromellose) to control drug release and withstand gastrointestinal peristalsis 2,5. In these formulations, croscarmellose sodium moisture content is maintained at 5–7% to ensure gradual swelling and matrix erosion over 8–12 hours. Higher moisture levels (>8%) can accelerate polymer hydration and premature drug release, while lower moisture (<5%) impairs matrix hydration and reduces release rate by 15–25% 2,5. Typical formulations contain 0.05–70% w/w API, 3–20% w/w croscarmellose sodium, 1–20% w/w alkali salt, and 1–20% w/w hydrophobic polymer, with total hygroscopic polymer content (croscarmellose sodium + hypromellose) maintained at 30–47% to balance release kinetics and tablet integrity 2,5,11,12,14.
Calcium phosphate (tricalcium phosphate) tablets utilize croscarmellose sodium at 0.5–1.0% w/w in combination with sodium lauryl sulfate (0.5–1.0% w/w, 50–100% of croscarmellose sodium weight) to enhance disintegration and calcium dissolution in the acidic gastric environment 3. Moisture content of croscarmellose sodium is maintained at 5–6% to prevent premature swelling during compression of the high-density calcium phosphate matrix (≥80% w/w), which requires compaction forces of 15–20 kN to achieve tablet hardness of 100–120 N 3. The synergistic effect of croscarmellose sodium and sodium lauryl sulfate reduces disintegration time
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| COMBE INCORPORATED | Topical body powder applications requiring enhanced moisture absorbency for wetness protection and skin irritation prevention in personal care products. | Body Powder Formulation | Croscarmellose sodium maintains fibrous structure at 5-20% w/w concentration, absorbing at least 20% moisture by weight without forming pasty gum, ensuring acceptable skin feel and appearance. |
| Shionogi & Co. Ltd. | Sustained release oral solid dosage forms requiring controlled drug release kinetics and mechanical stability in gastrointestinal tract for chronic disease management. | Extended Release Tablet Formulation | Croscarmellose sodium at 3-20% w/w combined with alkali salts and hydrophobic polymers controls drug dissolution over 8-12 hours while withstanding gastrointestinal peristalsis, maintaining matrix integrity throughout extended release period. |
| ORION CORPORATION | Immediate-release tablets for Parkinson's disease COMT inhibitors requiring rapid disintegration and dissolution while protecting moisture-sensitive active pharmaceutical ingredients. | Entacapone/Nitecapone Tablets | Croscarmellose sodium at 10-14% w/w achieves rapid disintegration under 3 minutes and dissolution exceeding 80% in 30 minutes for catechol derivatives, with moisture content maintained at 6-8% to balance disintegration efficiency and chemical stability. |
| FMC CORPORATION | High-compaction force tablet formulations and direct compression applications requiring superior disintegration performance in resource-limited or rapid-release pharmaceutical products. | Ac-Di-Sol Fine Particle Croscarmellose | Fine particle croscarmellose with median particle size 5-36 μm and specific surface area ≥0.3 m²/g provides enhanced disintegration efficiency, reducing tablet disintegration time to 30-45 seconds at 8 kN compaction force compared to 60-75 seconds for standard grades. |
| AMERICAN HOME PRODUCTS CORPORATION | Calcium supplement compressed tablets requiring effective disintegration of dense mineral matrices to ensure bioavailability of elemental calcium in nutritional supplementation applications. | Calcium Supplement Tablets | Croscarmellose sodium at 0.5-1.0% w/w combined with equal weight sodium lauryl sulfate enhances disintegration and calcium dissolution in acidic gastric environment for high-density calcium phosphate matrices (≥80% w/w) compressed at 15-20 kN. |